Dyne Therapeutics, Inc. faces a pivotal 2026 with key milestones for DYNE-101 and DYNE-251, supported by a well-timed $350M equity raise. The recent offering extends DYN's cash runway by roughly one ...

Enemy Intel Inflicting enough damage will pressure him. When his HP is reduced, he will fuse with scrap metal to perform powerful attacks. During this time, he will be difficult to pressure. However, ...

Battery-driven induction is starting to look like the next wave in cooking, with its superior performance potential and its compatibility with standard home wiring. It’s also got all the general ...

Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the high short interest stocks to buy right now. On December 8, Dyne Therapeutics announced positive topline results from the Registrational Expansion ...

Nine years after Sarepta Therapeutics’ Exondys 51 won a controversial FDA approval to treat a subset of patients with Duchenne muscular dystrophy (DMD), a challenger from Massachusetts biotech Dyne ...

The biotech announced a secondary stock issue. It aims to sell $300 million worth of common shares. Just after market close on Monday, Dyne announced that it has launched an underwritten public ...

WALTHAM, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven ...

Its No. 1 drug candidate did well in a clinical trial. It met both its primary and secondary endpoints. Before market open, Dyne announced that its zeleciment rostudirsen -- a treatment targeting the ...

Investors were haunted by the specter of share dilution. Just after market close on Monday, Dyne announced that it has launched an underwritten public offering of $300 million worth of its common ...

Gov. Terry McAuliffe broke ground on the new Puller Veterans Care Center in Fauquier County on Oct. 26. The 128-bed long-term care and rehabilitation facility will be built on 30 acres located on the ...